Topiramate in the treatment of obese subjects with drug‐naive type 2 diabetes

200676 citationsJournal Article

Authors

Kaj Stenlöf · Sahlgrenska University Hospital

S Rössner

Frank Vercruysse · Johnson & Johnson (United States)

Amit Kumar · Johnson & Johnson (United States)

M. Fitchet · Johnson & Johnson (United States)

Lars Sjöström · Sahlgrenska University Hospital

Study Group · Sahlgrenska University Hospital

Abstract

Topiramate as an add-on treatment to lifestyle improvements produced significant weight loss and improved glucose homeostasis in obese, drug-naive subjects with type 2 diabetes. These treatment advantages should be balanced against the occurrence of adverse events in the CNS.

Topics & Keywords

Pharmacology and Obesity Treatment Diabetes Treatment and Management Parkinson's Disease Mechanisms and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Diabetes Obesity and Metabolism

Volume 9, Issue 3, pp. 360-368

DOI: 10.1111/j.1463-1326.2006.00618.x

Field-Weighted Citation Impact: 4.18